Drugs / GNR-038
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04557319 | Mar → Aug 2020 | hereditary angioedema | AO GENERIUM | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04898309 | Dec 2021 → May 2023 | hereditary angioedema | AO GENERIUM | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GNR-038 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04898309 ↗ |
| Known as | rhC1-inh | “GNR-038 is a recombinant C1 inhibitor (rhC1-inh), which is a complete structural and functional analogue of the plasma C1 inhibitor.” NCT04557319 ↗ |
| Action | Restore | “The plasma/recombinant C1 inhibitor use to compensate for its deficiency or insufficient functional activity in patients with HAE is recommended both for severe and for...” NCT04557319 ↗ |
| Modality | Protein / enzyme biologic | “GNR-038 is a recombinant C1 inhibitor (rhC1-inh), which is a complete structural and functional analogue of the plasma C1 inhibitor.” NCT04557319 ↗ |
| Route | Intravenous | “intravenous infusion” NCT04557319 ↗ |